{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:08:32Z","timestamp":1789204112901,"version":"build-2803163510"},"reference-count":20,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epileptic Disorders"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the incidence of hostility\u2010 and aggression\u2010related adverse events in children with focal\u2010onset seizures (FOS), with or without focal to bilateral tonic\u2013clonic seizures (FBTCS), receiving perampanel as monotherapy or in combination with other antiseizure medications (ASMs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This analysis used a real\u2010world Japanese database integrating claims data, electronic medical records, and Diagnosis Procedure Combination data, alongside study\u2010specific physician\u2010reported outcomes. Children aged 4\u201311\u2009years treated with perampanel for FOS with or without FBTCS were included. Using a nested case\u2013control design, analyses adjusted for baseline covariates were conducted to compare the incidence of hostility\u2010 and aggression\u2010related adverse events in children treated with perampanel as monotherapy vs. combination therapy with other ASMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 158 prospectively collected patients included in the primary analysis set, 10 (6.3%) experienced 14 hostility\u2010 and aggression\u2010related adverse events, including irritability (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), aggression (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), anger (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092), anxiety (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091), and hallucinations (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). There were no significant differences in the risk of hostility or aggression between patients receiving perampanel as monotherapy or in combination with other ASMs. Secondary and sensitivity analyses confirmed the robustness of these findings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>The safety profile of perampanel in routine pediatric practice was consistent with prior clinical trial data. The potential for hostility\u2010 and aggression\u2010related adverse events warrants caution, but rates did not differ between perampanel as monotherapy vs. in combination with other ASMs. This study also demonstrated the feasibility of integrating physician\u2010reported outcomes into post\u2010marketing surveillance using a real\u2010world database, providing detailed insights beyond standard medical information.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/epd2.70399","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:40:48Z","timestamp":1789202448000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of hostility and aggression with perampanel monotherapy versus combination therapy in pediatric epilepsy: A Japanese post\u2010marketing database study using a nested case\u2013control design"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-8967","authenticated-orcid":false,"given":"Yukitoshi","family":"Takahashi","sequence":"first","affiliation":[{"name":"National Epilepsy Center NHO Shizuoka Institute of Epilepsy and Neurological Disorders  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2990-2687","authenticated-orcid":false,"given":"Masato","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Public Health Shizuoka Graduate University of Public Health  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2252-2081","authenticated-orcid":false,"given":"Akiko","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Clinical Planning and Development Department Eisai Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8718-0467","authenticated-orcid":false,"given":"Kasumi","family":"Daidoji","sequence":"additional","affiliation":[{"name":"Clinical Planning and Development Department Eisai Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2230-9555","authenticated-orcid":false,"given":"Kazuhiro","family":"Matsutani","sequence":"additional","affiliation":[{"name":"Clinical Planning and Development Department Eisai Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6747-3095","authenticated-orcid":false,"given":"Mika","family":"Ishii","sequence":"additional","affiliation":[{"name":"Global Safety Department Eisai Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1586947","article-title":"Developmental mechanisms underlying pediatric epilepsy","volume":"16","author":"Lolam V","year":"2025","journal-title":"Front Neurol"},{"issue":"6","key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial\u2010onset seizures: randomized phase III study 304","volume":"79","author":"French JA","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial\u2010onset seizures: results of randomized global phase III study 305","volume":"54","author":"French JA","year":"2013","journal-title":"Epilepsia"},{"issue":"1","key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1528-1167.2012.03648.x","article-title":"Perampanel, a selective, noncompetitive \u03b1\u2010amino\u20103\u2010hydroxy\u20105\u2010methyl\u20104\u2010isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial\u2010onset seizures: interim results from phase III, extension study 307","volume":"54","author":"Krauss GL","year":"2013","journal-title":"Epilepsia"},{"issue":"18","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial\u2010onset seizures","volume":"78","author":"Krauss GL","year":"2012","journal-title":"Neurology"},{"issue":"7","key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/epi.13417","article-title":"Adjunctive perampanel in adolescents with inadequately controlled partial\u2010onset seizures: a randomized study evaluating behavior, efficacy, and safety","volume":"57","author":"Lagae L","year":"2016","journal-title":"Epilepsia"},{"issue":"4","key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejpn.2015.02.008","article-title":"Efficacy and safety of perampanel in adolescent patients with drug\u2010resistant partial seizures in three double\u2010blind, placebo\u2010controlled, phase III randomized clinical studies and a combined extension study","volume":"19","author":"Rosenfeld W","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"issue":"8","key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff BJ","year":"2013","journal-title":"Epilepsia"},{"issue":"4","key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/epi.18242","article-title":"Long\u2010term safety and efficacy of adjunctive perampanel in pediatric patients (ages 4 to <12\u2009years) with inadequately controlled focal\u2010onset seizures or generalized tonic\u2010clonic seizures","volume":"66","author":"Flamini R","year":"2025","journal-title":"Epilepsia"},{"issue":"2","key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/epi.18193","article-title":"Efficacy and safety of perampanel in patients with seizures associated with Lennox\u2010Gastaut syndrome: a randomized trial","volume":"66","author":"Vossler DG","year":"2025","journal-title":"Epilepsia"},{"issue":"11","key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic\u2013clonic seizures in idiopathic generalized epilepsy a randomized trial","volume":"85","author":"French JA","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/epi.16413","article-title":"Open\u2010label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12\u2009years) with inadequately controlled focal seizures or generalized tonic\u2010clonic seizures","volume":"61","author":"Fogarasi A","year":"2020","journal-title":"Epilepsia"},{"issue":"5","key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/0883073819827407","article-title":"Adjunctive perampanel oral suspension in pediatric patients from \u22652 to <12\u2009years of age with epilepsy: pharmacokinetics, safety, tolerability, and efficacy","volume":"34","author":"Renfroe JB","year":"2019","journal-title":"J Child Neurol"},{"issue":"3","key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/pr.115.012021","article-title":"Epilepsy, antiepileptic drugs, and aggression: an evidence\u2010based review","volume":"68","author":"Brodie MJ","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"1","key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S0954579405050029","article-title":"Developmental foundations of externalizing problems in young children: the role of effortful control","volume":"17","author":"Olson SL","year":"2005","journal-title":"Dev Psychopathol"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yebeh.2016.10.013","article-title":"Evaluation of perampanel in patients with intellectual disability and epilepsy","volume":"66","author":"Snoeijen\u2010Schouwenaars FM","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"3","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.37737\/ace.24009","article-title":"A new electronic medical record database linked to claims data and discharge abstract data (the RWD database) in Japan: study design and profile","volume":"6","author":"Okumura Y","year":"2024","journal-title":"Ann Clin Epidemiol"},{"issue":"9","key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.seizure.2014.06.004","article-title":"Behavioral side\u2010effects of levetiracetam in children with epilepsy: a systematic review","volume":"23","author":"Halma E","year":"2014","journal-title":"Seizure"},{"issue":"1","key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/0883073811417183","article-title":"A long\u2010term open\u2010label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16\u2009years with partial\u2010onset seizures","volume":"27","author":"Schiemann\u2010Delgado J","year":"2012","journal-title":"J Child Neurol"},{"key":"e_1_2_11_21_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.924057","article-title":"Efficacy and adverse reactions of perampanel in the treatment of epilepsy in children","volume":"13","author":"Li D","year":"2022","journal-title":"Front Neurol"}],"container-title":["Epileptic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epd2.70399","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/epd2.70399","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epd2.70399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:40:56Z","timestamp":1789202456000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epd2.70399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":20,"alternative-id":["10.1002\/epd2.70399"],"URL":"https:\/\/doi.org\/10.1002\/epd2.70399","archive":["Portico"],"relation":{},"ISSN":["1294-9361","1950-6945"],"issn-type":[{"value":"1294-9361","type":"print"},{"value":"1950-6945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"2026-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"epd2.70399"}}